<DOC>
	<DOCNO>NCT00320736</DOCNO>
	<brief_summary>This study double-blind , placebo-controlled trial nicotinic receptor agonist , galantamine , improvement memory attention people schizophrenia schizoaffective disorder . Twenty subject stable dose antipsychotic medication receive galantamine identical placebo tablet 8 week . Adverse event screen every week . Tests memory , attention , reward responsivity perform baseline afer 8 week medication . Clinical scale rating psychiatric symptom perform begin , middle , end trial .</brief_summary>
	<brief_title>Galantamine Cognition People With Schizophrenia</brief_title>
	<detailed_description>Background : Galantamine novel acetylcholinesterase inhibitor also positive allosteric modulator nicotinic acetylcholine receptor . Galantamine show increase conductivity nicotinic receptor bind site discreet acetylcholine receptor . There minimal risk overstimulation positive allosteric modulators produce receptor depolarization potentiate submaximal acetylcholine induce depolarization . Our hypothesis allosteric modulation nicotinic acetylcholine receptor potentially important treatment strategy schizophrenia . We propose trial galantamine augmentation antipsychotic medication treatment schizophrenia test follow hypothesis . Hypotheses : 1 . Galantamine augmentation antipsychotic treatment associate improvement baseline performance cognitive battery : Stroop , Cornblatt CPT-IP , CDR Battery , letter number span , Grooved peg board , Tower London , Signal Detection Task . 2 . Galantamine augmentation high potency antipsychotic treatment well tolerate associate improvement baseline negative symptom ( SANS ) , depressive symptom ( CDSS ) impulsivity ( PANSS aggression item ) . Study Design : Twenty adult subject , age 18-60 , randomize , accord double blind , parallel group design , receive galantamine identical placebo 8 week . Subjects begin dose 8 mg twice per day first four week , 16 mg twice per day next four week . Visits weekly monitor medication compliance medication side effect . Prior begin treatment , subject undergo 1.5 hour training session familiarize CDR battery portion cognitive battery . Subjects evaluate symptoms psychosis , depression , anxiety , smoke behavior medication side effect standard clinical rating scale include Schedule Assessment Negative Symptoms ( SANS ) , Positive Negative Symptom Scale ( PANSS ) , Brief Psychiatric Rating Scale ( BPRS ) , Calgary Depression Scale Schizophrenia ( CDSS ) , Abnormal Involuntary Movement Scale ( AIMS ) , Simpson Angus Scale Barnes Akathisia Scale , Fagerstrom Test Nicotine Dependence , carbon monoxide measurement smoke self report . Subjects meet criterion current depression suicidal ideation exclude . Clinical rating scale perform baseline monthly . Tests visual spatial work memory , attention , motor skill , inhibition , motivation perform baseline 8 week . The cognitive battery include test response inhibition ( 3-card Stroop ) , attention ( Cornblatt continuous performance test identical pair ( CPT-IP ) CDR Battery ) , verbal memory ( CDR Battery ) , work memory ( letter-number span ) , non-verbal memory ( CDR Battery ) , psychomotor ability ( groove peg board task ) , executive functioning ( Tower London ) , motivation reward ( signal detection task ) . Blood drawn antipsychotic level , galantamine level , measurement nicotinic receptor number baseline 8 week . Adverse event document visit use Adverse Events Tracking log . At baseline week 8 carbon monoxide ( CO ) measurement use self report verify number cigarette smoke per day .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>1 . Diagnosis schizophrenia schizoaffective disorder depress type stable psychiatric symptom , active suicidal ideation 2 . Age 1860 , inclusive 3 . Stable medical condition hypertension , noninsulindependent diabetes , hypothyroidism allow 4 . Treated antipsychotic medication stable dose &gt; 4 week 5 . Not treated investigational medication past 30 day 6 . Competent provide inform consent 7 . WRAT3 IQ raw score great equal 35 8 . Expired CO level &lt; 9 ppm 9 . Salivary cotinine level &lt; 30 ng/ml 10 . Nonsmoker least 3 month 1 . Diagnosis dementia , neurodegenerative disease current Axis I DSMIV diagnosis 2 . Any unstable medical illness , asthma require daily treatment , severe COPD , active peptic ulcer disease , gastrointestinal bleeding , atrioventricular block , urinary outflow obstruction , history epilepsy 3 . Concurrent use anticholinergic medication use cholinomimetic medication past month , cogentin , donepezil clozapine 4 . Alcohol substance abuse past month ( selfreport confirm chart ) 5 . Known allergy hypersensitivity galantamine 6 . Current treatment erythromycin ketoconazole 7 . Concurrent use NSAIDs 8 . Women childbearing potential 9 . History suicide attempt past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>cognitive function</keyword>
	<keyword>cholinergic medication</keyword>
	<keyword>nicotinic receptor agonist</keyword>
</DOC>